Brown Brothers Harriman & Co’s Aerie Pharmaceuticals AERI Stock Holding History

Brown Brothers Harriman & Co’s Portfolio AERI Stock Details AERI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q2	–	Sell	-170	Closed	-$2K	–	1245
2020 Q1	$2K	Buy	+170	New	+$3.23K	﹤0.01%	959
2018 Q1	–	Sell	-113	Closed	-$7K	–	1192
2017 Q4	$7K	Buy	+113	New	+$6.85K	﹤0.01%	807

Other funds holding AERI

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

PHS

PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

LCS

Levin Capital Strategies New York $1.49B AUM 30.44% 1-Year Est. Return

FAM

Fred Alger Management New York $22.8B AUM 64.63% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

William Blair Investment Management Chicago, Illinois $30.3B AUM 33.75% 1-Year Est. Return

Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

RHJA

Rice Hall James & Associates San Diego, California $2.05B AUM 43.16% 1-Year Est. Return

Brown Brothers Harriman & Co's AERI Position: Q2 2020 in Review

Brown Brothers Harriman & Co sold out of Aerie Pharmaceuticals (AERI) in Q2 2020, closing a stake of 170 shares — an estimated $2K sold.

Brown Brothers Harriman & Co first reported a position in AERI in Q4 2017 and held it in 2 quarters. The position peaked at $7K in Q4 2017. 155 funds tracked by Wall St. Rank hold AERI as of Q2 2020.

Brown Brothers Harriman & Co reported no remaining Aerie Pharmaceuticals position as of Q2 2020 after selling out during the quarter.
Brown Brothers Harriman & Co sold 170 Aerie Pharmaceuticals shares in Q2 2020, an estimated $2K.
Brown Brothers Harriman & Co first reported a position in Aerie Pharmaceuticals in Q4 2017 and held it in 2 quarters.
Brown Brothers Harriman & Co's Aerie Pharmaceuticals position peaked at $7K in Q4 2017.
155 funds tracked by Wall St. Rank held Aerie Pharmaceuticals as of Q2 2020.

Based on Brown Brothers Harriman & Co's 13F filing for Q2 2020, filed 13 Aug 2020.